[ad_1]
In China, medical personnel who were exposed to the infection in July began receiving urgent vaccinations.
Subsequently, quarantine officers at the border, overseas exits, and international students also received a vaccine in the development stage.
Although the vaccine has not been validated, some volunteer to get it.
[긴급 접종 지원자 (여성) : 내일 접종 받으면 좋고 안되면 모레 올게요.] [긴급 접종 지원자 (남성) : 우리는 해외에서 일해요. 장사하고 있어요.]There are even reports that a “scalp merchant”, who sells reserve tickets, showed up while people waited for the crowded shots.
The New York Times newspaper feared that this type of emergency vaccination would outweigh the benefits.
There are already 1 million people who have received emergency vaccines from China made by the state company Sinoparm.
Chinese authorities said the process had preventive effects and that there were no serious side effects.
[정중웨이 / 중국 국가위생건강위 과기발전센터 소장 : 코로나19 백신을 긴급 사용한 사람 가운데 엄중한 부작용은 아직 보고되지 않았습니다.]Chinese companies, however, do not give specific figures on efficiency.
However, this does not mean that the speed of development is slow, and it is a position that we only know when the phase 3 clinical trial ends.
[류징전 / 국유제약회사 시노팜 대표 : 3기 임상 실험을 통해 안정성과 예방력 관련 데이터를 수집한 뒤에 백신 심사를 통과해서 허가를 받은 뒤에 시판할 것입니다.]The director of the Center for Disease Control and Prevention, Gaofu, evaluated the effectiveness of the Pfizer and Modena vaccines.
However, no vaccine has passed the final test, and the Chinese vaccine is also very effective.
China plans to supply the vaccine to other countries at low cost once development is complete.
While the United States struggles with COVID-19, it is seen as an opportunity to increase the international impact of healthcare.
Reporter: Sungwoong Kang
Video Editing: Lim Hyeon-cheol
Graphics: Myunghwa Hong
Subtitle News: Park Hae Jin
